Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1755 ARTÍCULOS , VIENDO DEL 586 AL 600

Recruitment of Older African Americans in Alzheimer's Disease Clinical Trials Using a Community Education Approach

Shaw AR, Perales-Puchalt J, Moore T, Weatherspoon P, Robinson M, Hill CV, Vidoni ED.

J Prev Alzheimers Dis. 2022;9(4):672-678. doi: 10.14283/jpad.2022.82.

Oral Tau Aggregation Inhibitor for Alzheimer's Disease: Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

Wischik CM, Bentham P, Gauthier S, Miller S, Kook K, Schelter BO.

J Prev Alzheimers Dis. 2022;9(4):780-790. doi: 10.14283/jpad.2022.63.

Precuneus magnetic stimulation for Alzheimer's disease: a randomized, sham-controlled trial

Koch G, Casula EP, Bonnì S, Borghi I, Assogna M, Minei M, Pellicciari MC, Motta C, D'Acunto A, Porrazzini F, Maiella M, Ferrari C, Caltagirone C, Santarnecchi E, Bozzali M, Martorana A.

Brain. 2022 Nov 21;145(11):3776-3786. doi: 10.1093/brain/awac285.

Myelin repair in Alzheimer's disease: a review of biological pathways and potential therapeutics

Hirschfeld LR, Risacher SL, Nho K, Saykin AJ.

Transl Neurodegener. 2022 Oct 26;11(1):47. doi: 10.1186/s40035-022-00321-1.

Amyloidogenesis and Neurotrophic Dysfunction in Alzheimer's Disease: Do They have a Common Regulating Pathway?

Jiao F, Jiang D, Li Y, Mei J, Wang Q, Li X.

Cells. 2022 Oct 12;11(20):3201. doi: 10.3390/cells11203201.

From Small Peptides to Large Proteins against Alzheimer'sDisease

Picone P, Sanfilippo T, Vasto S, Baldassano S, Guggino R, Nuzzo D, Bulone D, San Biagio PL, Muscolino E, Monastero R, Dispenza C, Giacomazza D.

Biomolecules. 2022 Sep 22;12(10):1344. doi: 10.3390/biom12101344.

Alzheimer's Disease: Challenges and a Therapeutic Opportunity to Treat It with a Neurotrophic Compound

Baazaoui N, Iqbal K.

Biomolecules. 2022 Oct 2;12(10):1409. doi: 10.3390/biom12101409.

The Role of Clusterin Transporter in the Pathogenesis of Alzheimer's Disease at the Blood-Brain Barrier Interface: A Systematic Review

Fareed MM, Qasmi M, Aziz S, Völker E, Förster CY, Shityakov S.

Biomolecules. 2022 Oct 10;12(10):1452. doi: 10.3390/biom12101452.

Epigenetic Changes and Chromatin Reorganization in Brain Function: Lessons from Fear Memory Ensemble and Alzheimer's Disease

van Zundert B, Montecino M.

Int J Mol Sci. 2022 Oct 11;23(20):12081. doi: 10.3390/ijms232012081.

E2F4DN Transgenic Mice: A Tool for the Evaluation of E2F4 as a Therapeutic Target in Neuropathology and Brain Aging

Ramón-Landreau M, Sánchez-Puelles C, López-Sánchez N, Lozano-Ureña A, Llabrés-Mas AM, Frade JM.

Int J Mol Sci. 2022 Oct 11;23(20):12093. doi: 10.3390/ijms232012093.

Amyloid β, Lipid Metabolism, Basal Cholinergic System, and Therapeutics in Alzheimer's Disease

Campos-Peña V, Pichardo-Rojas P, Sánchez-Barbosa T, Ortíz-Islas E, Rodríguez-Pérez CE, Montes P, Ramos-Palacios G, Silva-Adaya D, Valencia-Quintana R, Cerna-Cortes JF, Toral-Rios D.

Int J Mol Sci. 2022 Oct 11;23(20):12092. doi: 10.3390/ijms232012092.

Lipopolysaccharides (LPSs) as Potent Neurotoxic Glycolipids in Alzheimer's Disease (AD)

Zhao Y, Jaber VR, Pogue AI, Sharfman NM, Taylor C, Lukiw WJ.

Int J Mol Sci. 2022 Oct 21;23(20):12671. doi: 10.3390/ijms232012671.

Physiological and Pathological Remodeling of Cerebral Microvessels

Tregub PP, Averchuk AS, Baranich TI, Ryazanova MV, Salmina AB.

Int J Mol Sci. 2022 Oct 21;23(20):12683. doi: 10.3390/ijms232012683.

Polypharmacy in Older Adults with Alzheimer's Disease

Esumi S, Ushio S, Zamami Y.

Medicina (Kaunas). 2022 Oct 13;58(10):1445. doi: 10.3390/medicina58101445.

Targeting Alzheimer's Disease: The Critical Crosstalk between the Liver and Brain

Huang Z, Lin HWK, Zhang Q, Zong X.

Nutrients. 2022 Oct 14;14(20):4298. doi: 10.3390/nu14204298.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias